Tomoko Hara-Oh

Div Of Experimental Chemotherapy, 3-8-31, Koto Ku
Ariake, 1358550, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.

3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.

Journal: Biochemical and biophysical research communications

Published: June 10, 2024

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.

Journal: NPJ precision oncology

Published: November 06, 2023

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization.

Journal: NPJ precision oncology

Published: October 30, 2023

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.

MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.

Journal: JCI insight

Published: July 06, 2023

Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.

Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.

Journal: Cancer letters

Published: April 12, 2022

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

Journal: NPJ precision oncology

Published: October 01, 2020

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.

Journal: Nature communications

Published: May 14, 2020

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.

Journal: Thoracic cancer

Published: November 05, 2019

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.

Journal: Nature communications

Published: September 14, 2018

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.

Journal: EBioMedicine

Published: August 08, 2018

3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.

3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.

Journal: Biochemical and biophysical research communications

Published: May 01, 2018

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 03, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026